Clinical factors associated with development of severe-complicated clostridium difficile infection

Clinical Gastroenterology and Hepatology

Volumn 11, Issue 11, 2013, Pages 1466-1471

  Shivashankar, Raina ^a   Khanna, Sahil ^a   Kammer, Patricia P ^a   Harmsen, W Scott ^a   Zinsmeister, Alan R ^a   Baddour, Larry M ^a   Pardi, Darrell S ^a  

^a MAYO CLINIC   (United States)

Author keywords

Antibiotic Resistant Bacteria; Database Analysis; PPI Use; Risk Factor

Indexed keywords

ANTIBIOTIC AGENT; ATROPINE PLUS DIPHENOXYLATE; BISMUTH SALICYLATE; CREATININE; HISTAMINE H2 RECEPTOR ANTAGONIST; LOPERAMIDE; NARCOTIC AGENT; PROCHLORPERAZINE; PROTON PUMP INHIBITOR;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; COLON RESECTION; COMORBIDITY; CREATININE BLOOD LEVEL; DEATH; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; INFECTION COMPLICATION; INFECTION RISK; INTENSIVE CARE UNIT; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; SECONDARY ANALYSIS; UNITED STATES;

ANTIBIOTIC RESISTANT BACTERIA; CDI; CI; CLOSTRIDIUM DIFFICILE INFECTION; CONFIDENCE INTERVAL; DATABASE ANALYSIS; ICU; INTENSIVE CARE UNIT; ODDS RATIO; OR; PCR; POLYMERASE CHAIN REACTION; PPI; PPI USE; PROTON PUMP INHIBITOR; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; ROC;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; INTENSIVE CARE; MALE; MIDDLE AGED; MINNESOTA; RISK FACTORS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84885837589     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.04.050     Document Type: Article

References (22)

1. Kelly C.P., LaMont J.T. Clostridium difficile: more difficult than ever. NEngl J Med 2008, 359:1932-1940.
2. Khanna S., Pardi D.S., Aronson S.L., et al. The epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am J Gastroenterol 2011, 107:89-95.
3. Khanna S., Pardi D.S. The growing incidence and severity of Clostridium difficile infection in inpatient and outpatient settings. Expert Rev Gastroenterol Hepatol 2010, 4:409-416.
4. Cohen S.H., Gerding D.N., Johnson S., et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010, 31:431-455.
5. Fujitani S., George W.L., Murthy A.R. Comparison of clinical severity score indices for Clostridium difficile infection. Infect Control Hosp Epidemiol 2011, 32:220-228.
6. Lungulescu O.A., Cao W., Gatskevich E., et al. CSI: a severity index for Clostridium difficile infection at the time of admission. JHosp Infect 2011, 79:151-154.
7. Rubin M.S., Bodenstein L.E., Kent K.C. Severe Clostridium difficile colitis. Dis Colon Rectum 1995, 38:350-354.
8. McEllistrem M.C., Carman R.J., Gerding D.N., et al. Ahospital outbreak of Clostridium difficile disease associated with isolatescarrying binary toxin genes. Clin Infect Dis 2005, 40:265-272.
9. Louie T.J., Peppe J., Watt C.K., et al. Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Clin Infect Dis 2006, 43:411-420.
10. Belmares J., Gerding D.N., Parada J.P., et al. Outcome of metronidazole therapy for Clostridium difficile disease and correlation with a scoring system. JInfect 2007, 55:495-501.
11. Zar F.A., Bakkanagari S.R., Moorthi K.M., et al. Acomparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007, 45:302-307.
12. Gujja D., Friedenberg F.K. Predictors of serious complications due to Clostridium difficile infection. Aliment Pharmacol Ther 2009, 29:635-642.
13. Louie T., Gerson M., Grimard D. Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in Clostridium difficile-associated diarrhea (CDAD). Program and abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy 2007, American Society for Microbiology, Washington, DC, abstract K425a.
14. University of Pittsburgh Medical Center. Guide to antimicrobial chemotherapy. 4th ed. 2008. Available at: Accessed November2011. http://www.residency.dom.pitt.edu/Hcorner/Documents/AntimicrobialGuide2008.pdf.
15. Khanna S., Pardi D.S., Rosenblatt J.E., et al. An evaluation of repeat stool testing for Clostridium difficile infection by polymerase chain reaction. JClin Gastroenterol 2012, 46:846-849.
16. Guzzo T.J., Dluzniewski P., Orosco R., et al. Prediction of mortality after radical prostatectomy by Charlson Comorbidity Index. Urology 2010, 76:553-557.
17. Mullane K.M., Miller M.A., Weiss K., et al. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis 2011, 53:440-447.
18. Ananthakrishnan A.N., Guzman-Perez R., Gainer V., et al. Predictors of severe outcomes associated with Clostridium difficile infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2012, 35:789-795.
19. Morrison R.H., Hall N.S., Said M., et al. Risk factors associated with complications and mortality in patients with Clostridium difficile infection. Clin Infect Dis 2011, 53:1173-1178.
20. Lichtenstein G.R., Feagan B.G., Cohen R.D., et al. Serious infectionsand mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006, 4:621-630.
21. Manek K., Williams V., Callery S., et al. Reducing the risk of severe complications among patients with Clostridium difficile infection. Can J Gastroenterol 2011, 25:368-372.
22. Pant C., Sferra T.J., Ondrade C., et al. Serum markers for severe Clostridium difficile infection in immunosuppressed hospitalized patients. JLa State Med Soc 2011, 163:91-94.